Comparison of exposure response relationship of atrasentan between N orth A merican and A sian populations
- 15 December 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (4) , 545-552
Abstract
Aims: The selective endothelin ( ET ) A receptor antagonist atrasentan has been shown to lower albuminuria in N orth A merican and A sian patients with type 2 diabetes and nephropathy. As drug responses to many drugs may differ between N orth A merican and A sian populations, we assessed the influence of geographical region on the albuminuria and fluid retention response to atrasentan. Materials and methods: Two 12‐week double‐blind randomised controlled trials were performed with atrasentan 0.75 or 1.25 mg/d vs placebo in patients with type 2 diabetes and nephropathy. The efficacy endpoint was the percentage change in albuminuria. Bodyweight change, a proxy of fluid retention, was used as a safety endpoint. Pharmacodynamics were determined in A sians ( N = 77) and N orth A mericans ( N = 134). Atrasentan plasma concentration was measured in 161 atrasentan‐treated patients. Results: Mean albuminuria reduction in Asian, compared to N orth A merican, patients was, respectively, −34.4% vs −26.3% for 0.75 mg/d ( P = .44) and −48.0% vs −28.9% for 1.25 mg/d ( P = .035). Bodyweight gain did not differ between N orth A merican and A sian populations. Atrasentan plasma concentrations were higher in A sians compared to N orth A mericans and correlated with albuminuria response (7.2% albuminuria reduction per doubling atrasentan concentration; P = .024). Body surface area (β = −1.09 per m 2 ; P < .001) and bilirubin, as a marker of hepatic organic anion transporter activity, (β = 0.69 per mg/ dL increment; P = .010) were independent determinants of atrasentan plasma concentration; correction by body surface area and bilirubin left no significant difference in plasma concentration between A sian and N orth A merican populations. Conclusion: The higher exposure and albuminuria reduction of atrasentan in A sian patients is not associated with more fluid retention, suggesting that A sian patients are less sensitive to atrasentan‐induced sodium retention.Keywords
Funding Information
- AbbVie
This publication has 20 references indexed in Scilit:
- Endothelin antagonists for diabetic and non‐diabetic chronic kidney diseaseBritish Journal of Clinical Pharmacology, 2013
- Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockersKidney International, 2012
- Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitroCancer Chemotherapy and Pharmacology, 2011
- Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humansJournal of Pharmacokinetics and Pharmacodynamics, 2010
- Ethnic Differences in Cardiovascular Drug ResponseCirculation, 2008
- Comparison of SLCO1B1 sequence variability among German, Turkish, and African populationsEuropean Journal of Clinical Pharmacology, 2008
- SNPassoc: an R package to perform whole genome association studiesBioinformatics, 2007
- Effect of body weight on the volume of distribution of theophyllineLung, 1988
- A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.British Journal of Clinical Pharmacology, 1986
- The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and TriazolamClinical Pharmacokinetics, 1984